Fatty Liver Is More Than "Fat in the Liver": The MASLD Rename, How to Calculate FIB-4, Who Needs Fibrosis Testing, and How Much Weight Loss Works

Why the name changed: from NAFLD to MASLD

In 2023 the American, European and Latin American liver societies renamed "non-alcoholic fatty liver disease (NAFLD)" to MASLD — metabolic dysfunction-associated steatotic liver disease [1]. Two reasons: the old name defined a disease by what it is not, and "fatty" was felt to be stigmatising.

The new definition: hepatic steatosis (≥5% of hepatocytes) plus at least one cardiometabolic risk factor:

• BMI ≥25 (≥23 in Asians) or increased waist circumference
• Fasting glucose ≥100 mg/dL, HbA1c ≥5.7%, or type 2 diabetes
• BP ≥130/85 or on antihypertensives
• Triglycerides ≥150 mg/dL
• HDL <40 mg/dL men, <50 women

"NASH" became MASH; those who also drink moderately are classified as MetALD [1].

How common, and why it matters

Global adult prevalence is about 30% and rising; Asia is around 30%, with Taiwanese and Japanese studies reporting 25–35% [2][3]. Most people never progress, but 20–30% develop MASH (inflammation and hepatocyte injury), and a proportion progress to fibrosis → cirrhosis → liver cancer [2][3].

Crucially, the leading cause of death in MASLD is cardiovascular disease, with liver disease second [2][3]. MASLD co-exists strongly with type 2 diabetes and CKD — MASLD roughly raises CKD risk 1.5-fold [4].

What predicts outcome? Fibrosis stage, not fat

Studies consistently show that fibrosis stage (F0–F4), not the amount of fat or the ALT level, is the strongest predictor of liver-related death [2][3]. A normal ALT does not exclude fibrosis.

Step 1: FIB-4 (a blood test you already have)

Both AASLD and EASL recommend FIB-4 as the first-line test [2][3]:

FIB-4 = (age × AST) ÷ (platelets × √ALT)

FIB-4 may under-estimate in people <35** and over-estimate **>65 (EASL suggests a lower cut-off of 2.0 above 65) [3]. This site has a FIB-4 calculator.

Step 2: liver stiffness (VCTE)

FibroScan measures stiffness in kPa: <8 kPa makes advanced fibrosis unlikely; ≥12 kPa likely; in between needs further work-up [2][3]. Biopsy remains the gold standard but is rarely needed.

Who should be screened?

AASLD 2023 recommends proactively calculating FIB-4 in [2]:

• Type 2 diabetes
• Obesity with ≥1 metabolic risk factor
• Incidental steatosis on imaging or persistently raised ALT
• First-degree relative with cirrhosis

Treatment: weight loss remains the cornerstone — with clear numbers

How:

• Diet: the Mediterranean pattern has the strongest evidence (reduces liver fat even without weight change); cut fructose (sugary drinks) and ultra-processed food; coffee (≥3 cups/day, unsweetened) is associated with less fibrosis [2][3].
• Exercise: 150–300 min/week moderate aerobic plus resistance training; reduces liver fat even without weight loss [3].
• Alcohol: minimise; abstain completely with advanced fibrosis [2][3].

Medications

• Resmetirom (thyroid hormone receptor-β agonist): FDA-approved in 2024 for MASH with F2–F3 fibrosis; in MAESTRO-NASH, MASH resolution at one year was 26–30% vs 10% placebo and fibrosis improvement 24–26% vs 14% [5]. Not yet available in Taiwan or Japan (mid-2026).
• GLP-1 receptor agonists (semaglutide, tirzepatide): act largely through weight loss; the phase 3 ESSENCE trial showed MASH resolution and fibrosis improvement with semaglutide; appropriate with coexisting diabetes or obesity [3][6].
• SGLT2 inhibitors, pioglitazone: consider in type 2 diabetes; evidence for reduced liver fat and histological improvement [2][3].
• Vitamin E (800 IU/day): may be considered in non-diabetic MASH, with long-term safety concerns [2].
• No good evidence: "liver-protective" supplements and milk thistle (silymarin) lack high-quality data and must not replace weight loss [2].

Notes for kidney patients and transplant recipients

• MASLD and CKD share metabolic causes; a single FIB-4 is reasonable in CKD, but CKD may lower platelets and inflate FIB-4 — interpret with hepatology.
• After transplant, steroids, tacrolimus and weight gain promote steatosis; post-transplant diabetes raises risk further.
• Pioglitazone causes fluid retention — caution in CKD and heart failure.
• Check weight-loss drugs against anti-rejection medication with your transplant team.

When to seek care

Urgently: yellow skin or eyes, vomiting blood or black stools, rapid abdominal swelling, confusion or drowsiness (complications of cirrhosis).

Routine appointment: FIB-4 >1.3, ALT persistently above the upper limit, diabetes with no liver assessment ever, or a first-degree relative with cirrhosis or liver cancer.

Questions to ask your doctor

1. What is my FIB-4? Do I need a FibroScan?
2. Do I have advanced fibrosis? How often should I be followed, and should I be screened for liver cancer?
3. What does 7–10% weight loss mean in kilograms for me? Can a dietitian help?
4. Could my diabetes medication be switched to one that also helps the liver (SGLT2i, GLP-1 RA)?
5. Should I stop any of my supplements?

References

1. Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. https://doi.org/10.1097/HEP.0000000000000520
2. Rinella ME, et al. AASLD Practice Guidance on NAFLD. Hepatology. 2023;77(5):1797–1835. https://doi.org/10.1097/HEP.0000000000000323
3. EASL–EASD–EASO Clinical Practice Guidelines on MASLD. J Hepatol. 2024;81(3):492–542. https://doi.org/10.1016/j.jhep.2024.04.031
4. Mantovani A, et al. NAFLD and risk of incident CKD: updated meta-analysis. Gut. 2022;71(1):156–162. https://doi.org/10.1136/gutjnl-2020-323082
5. Harrison SA, et al. MAESTRO-NASH. N Engl J Med. 2024;390(6):497–509. https://doi.org/10.1056/NEJMoa2309000
6. Sanyal AJ, et al. ESSENCE. N Engl J Med. 2025;392(21):2089–2099. https://doi.org/10.1056/NEJMoa2413258

This article compiles publicly available medical information for educational purposes only. It is not medical advice and has not been reviewed by a practising physician. For any health or medication question, consult a qualified professional. For chest pain, sudden breathlessness, one-sided weakness or slurred speech, call your local emergency number or go to the emergency department immediately.